Cardurion Pharmaceuticals Inc. raised $260m in series B venture capital to fund ongoing Phase II clinical trials in heart failure and a rare genetic arrhythmic disease for its two lead drug candidates as well as in-house discovery work and external sourcing of novel drug candidates. The company’s clinical-stage programs came from outside sources, and it continues to search for first-in-class cardiovascular disease medicines at a time when dealmaking in the cardiometabolic space is getting increasingly competitive.
Key Takeaways
-
Cardurion raised $260m in series B venture capital to fund Phase II clinical trials of its PDE9 inhibitor in heart failure and its CaMKII inhibitor in a rare genetic arrhythmic disease.
“No question, there is renewed interest in the space,” Cardurion CEO Peter Lawrence told Scrip. But while cardiovascular drug development...
